Dyne Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share data) | 2023 | 2022 |
| Operating expenses: | ||
| Research and development | $210,762 | $142,760 |
| General and administrative | 31,400 | 28,202 |
| Total operating expenses | 242,162 | 170,962 |
| Loss from operations | (242,162) | (170,962) |
| Other (expense) income: | ||
| Interest income | 7,641 | 2,917 |
| Other income (expense), net | (1,416) | (54) |
| Total other (expense) income, net | 6,225 | 2,863 |
| Net loss | $(235,937) | $(168,099) |
| Net loss per share, basic and diluted | $(3.95) | $(3.23) |
| Weighted average common shares outstanding, basic and diluted | 59,683,851 | 51,976,343 |
| Comprehensive loss: | ||
| Net loss | $(235,937) | $(168,099) |
| Other comprehensive loss: | ||
| Unrealized gains (losses) on marketable securities, net | 571 | (302) |
| Comprehensive loss | $(235,366) | $(168,401) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.